More Americans are turning to diabetes drugs like Ozempic, not for diabetes, but for weight loss. A new study shows that the use of GLP-1 medications among U.S. adults without diabetes more than tripled between 2018 and 2022. In that time, annual spending on these drugs surged from $1.6 billion to $5.8 billion. GLP-1 drugs,
A recent survey by ixlayer and Ipsos reveals that patients expect pharmaceutical companies to do more than just develop medications—they want digital tools to improve healthcare access. Over 400 adults with chronic conditions like asthma, diabetes, and heart disease participated in the study, with nearly 75% saying they would welcome more support from drugmakers in
The FDA has approved Novo Nordisk’s drug Ozempic for a new use: reducing the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in adults with Type 2 diabetes and chronic kidney disease (CKD). This approval is significant because Ozempic is now the first drug in its class (GLP-1 receptor agonists) with
Novo Nordisk is exploring a higher-dose version of semaglutide to enhance weight loss treatments. In a recent phase 3b clinical trial called STEP UP, a 7.2-mg weekly dose of semaglutide helped participants lose an average of 20.7% of their body weight over 72 weeks. This significantly outperformed the 2.4-mg dose marketed as Wegovy, which led
Arrowhead Pharmaceuticals announced positive results from its Phase 3 PALISADE study on plozasiran, a new drug for treating familial chylomicronemia syndrome (FCS). FCS is a rare genetic condition that causes extremely high triglyceride levels, leading to serious health issues like acute pancreatitis. Currently, there are no approved treatments for FCS in the United States or
Merck & Co.’s new vaccine, CAPVAXIVE (V116), has been approved by the FDA for preventing invasive diseases and pneumonia in adults 18 and older caused by specific strains of the bacteria Streptococcus pneumoniae. This vaccine is particularly aimed at protecting adults over 50 from around 84% of invasive pneumococcal diseases. In several studies, CAPVAXIVE showed
Today the Team at JoinAStudy.ca would like to acknowledge the dedicated work of one of our Investigators, Dr. Sabeen Anwar. Dr. Anwar and her team have played a key part in gathering new data to advance the knowledge of patient care for the condition of Psoriatic Arthritis. The APPRAISE study, a prospective observational investigation conducted
Researchers at the Max Planck Institute for Infection Biology in Berlin have made a discovery regarding the autoimmune disease lupus, shedding light on a mechanism that can trigger the disease in children. Lupus is characterized by severe inflammation throughout the body, leading to significant impacts on affected individuals’ lives. The research focuses on a specific immune
Merck & Co. has presented data from a phase 3 trial showcasing the potential of its pneumococcal vaccine candidate, V116, to rival Pfizer’s current market dominance in vaccines of this nature. In the United States, Prevnar 20 (Pfizer’s vaccine) currently commands a dominant 95% share. However, Merck contends that V116 offers broader protection, making it
Regeneron Pharmaceuticals and Sanofi have announced positive results from their phase 3 trial, titled NOTUS, evaluating Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD). The trial demonstrated that Dupixent significantly reduced COPD exacerbations by 34% (compared to placebo) in patients with moderate-to-severe COPD who also show evidence of type 2 inflammation of
